We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cyprotex | LSE:CRX | London | Ordinary Share | GB00BP25RZ14 | ORD £0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 160.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCRX
RNS Number : 9255O
Cyprotex PLC
11 November 2016
Cyprotex PLC
("Cyprotex" or "the Company")
Director Dealing
Cyprotex PLC (AIM: CRX), a specialist Contract Research Organisation, announces that it was notified on 10 November 2016 that, on 10 November 2016, Steve Harris, Non-Executive Director, transferred 80,000 ordinary shares of 1p each in the Company ("Ordinary Shares") from an account in his own name to his wife Susan Harris for nil consideration by way of a gift. Following this transfer, Steve Harris' beneficial interest in the Company's Ordinary Shares remains unchanged at 235,514 Ordinary Shares, representing 1.05% of the Company's total issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities / person closely associated --- ------------------------------------------------------- a) Name Ralph Steve Harris --- ------------------------- ---------------------------- 2 Reason for the notification --- ------------------------------------------------------- a) Position/status Non- Executive Director of Cyprotex PLC --- ------------------------- ---------------------------- b) Initial notification Initial Notification /Amendment --- ------------------------- ---------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- ------------------------------------------------------- a) Name Cyprotex PLC --- ------------------------- ---------------------------- b) LEI N/A --- ------------------------- ---------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- ------------------------------------------------------- a) Description of Ordinary Shares of 1p each the financial instrument, type of instrument ISIN Code: GB00BP25RZ14 Identification code --- ------------------------- ---------------------------- b) Nature of the Transfer of Ordinary Shares transaction --- ------------------------- ---------------------------- c) Price(s) and volume(s) Price(s): Volume(s): N/A 80,000 --- ------------------------- ---------------------------- d) Aggregated information N/A - Aggregated volume - Price --- ------------------------- ---------------------------- e) Date of the transaction 10/11/2016 --- ------------------------- ---------------------------- f) Place of the transaction London Stock Exchange --- ------------------------- ----------------------------
For further information:
Cyprotex PLC Tel: +44 (0) 1625 505 100 Dr Anthony Baxter, Chief Executive ir@cyprotex.com Officer www.cyprotex.com John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel N+1 Singer (Nomad & Broker) Tel: +44 (0)20 7496 3000 Shaun Dobson shaun.dobson@n1singer.com Jen Boorer jennifer.boorer@n1singer.com www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is quoted on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe(R) PK, chemPK(TM) and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHGGGQPGUPQPUU
(END) Dow Jones Newswires
November 11, 2016 02:00 ET (07:00 GMT)
1 Year Cyprotex Chart |
1 Month Cyprotex Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions